Don't you need to be concerned with wash sales? You seem to be constantly selling for a loss, and then buying back at a lower price. The problem with a stock like this is you just can't buy it cheap enough.
Initiating coverage? These analysts now want to pretend they never heard of Compugen, or they made big mistakes in the past?
Ms. Wang might be trying to get her clients out too. She was pumping hard at $14. You know her investors are now underwater and drowning too. Why did she lower her price target from $14 to $11? Hardly seems like an upgrade.
One thing appears consistent. Her upgrade at Oppenheimer didn't have any more benefit to the stock price than her upgrade at Chardan Capital.
You are better informed than me...didn't realise Ms Wang was with Oppenheimer....are you sure?
Wang is a common name in China, and no, I didn't call her to ask her if she is the same Ms. Wang. It is interesting to note though that she is also an Ivy League graduate.
That analyst upgrade had a positive impact for 23 minutes. The stock has moved back into the red now, and I'm unaware that Ms. Wang had anything new to say.
This is the same Ms. Wang from Chardan Capital Markets, and the dilution from the botched secondary was much, much more than 16%.
Isn't this the same analyst who had a $14 target previously? Dropped price target from $14 to $11 and said nothing new?
"It seems we have very little credibility with the investment community that matters"
This is an honest and accurate statement.
"updated presentation but nothing new which prompts me to ask why Anat appeared at the Jefferies Conference!"
The weather in Boston is great this time of year and the food is always good too. Who wouldn't want to go especially when they have somebody else footing the whole bill? The company has to do something with all that money raised in the botched secondary offering.
"If we do not get some meaningful revenue this year we will have to dilute next year."
Another botched secondary is coming next year?
"In my view, given the article cited in the first post of this thread, this is an important announcement."
If it was important, the stock would be going up and not down. Broken promises regarding commercial deals are important. This is not.
If you are looking for up, up and away, then buy Invivo Therapeutics. The company is headquartered in Cambridge, Mass. I'm sure the Ivy League graduates on this message board can tell you where that is located.
You are correct. My posts have no negative impact, but Gerstal's statements and broken promises do. Anat is attending more conferences, yet the stock still can't hold $7. The stock is now down over 50% since the bungled secondary was first announced.